SRRK — Scholar Rock Holding Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1727196 ·
Last close
$47.29
Market Cap
$5.67B
52W High
$58.49
52W Low
$43.23
ADV30
1,597,867
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -102,016,000 | -105,510,000 | 535,254,000 | 430,543,000 | 259,241,000 |
| Dec 2025 | 0 | — | -91,896,000 | -90,965,000 | 404,272,000 | 323,527,000 | 158,784,000 |
| Sep 2025 | 0 | — | -103,550,000 | -102,220,000 | 411,718,000 | 286,770,000 | 166,723,000 |
| Jun 2025 | 0 | — | -112,109,000 | -110,031,000 | 340,045,000 | 152,925,000 | 106,752,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-300,035,000
Investing CF
$218,687,000
Financing CF
$228,399,000
CapEx
$-602,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.43
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,300,654,000
Inventory
—
Receivables
$2,799,000
ST Investments
$44,036,000
EBIT TTM
$-375,232,000
Pretax Income TTM
$-377,939,000
Interest Exp TTM
$5,074,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -384,645,000 | -377,939,000 | 404,272,000 | 158,784,000 | — | -300,035,000 |
| Dec 2024 | 0 | -252,054,000 | -246,294,000 | 474,922,000 | 106,288,000 | — | -200,949,000 |
| Dec 2023 | 0 | -171,295,000 | -165,789,000 | 311,035,000 | 85,817,000 | — | -145,226,000 |
| Dec 2022 | 33,193,000 | -134,370,000 | -134,502,000 | 358,168,000 | 97,933,000 | — | -132,694,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TWST | Twist Bioscience Corp | $5.70B | $91.55 | — |
| CGON | CG Oncology, Inc. | $6.28B | $71.19 | — |
| CRSP | CRISPR Therapeutics AG | $4.73B | $47.99 | — |
| IBRX | ImmunityBio, Inc. | $7.51B | $7.17 | — |
| PCVX | Vaxcyte, Inc. | $7.81B | $54.08 | — |
News headlines (Yahoo Finance, 1h cache)
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-07-29 12:00 · Yahoo
Scholar Rock Holding (SRRK) Pulls Back Following A Strong Run, Is It Trading At A Discount?
2026-07-29 06:07 · Yahoo
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
2026-07-20 12:00 · Yahoo
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
2026-07-20 08:54 · Yahoo
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 20:15 · Yahoo
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-16 12:00 · Yahoo
Three Biotechs That Are Top Takeover Targets
2026-05-18 17:55 · Yahoo
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
2026-05-14 19:05 · Yahoo
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
2026-05-14 18:57 · Yahoo
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
2026-05-14 18:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.